Miltefosine: new preparation. Solution for cutaneous application

In patients with breast cancer and skin metastases, topically applied miltefosine solution yields at least partial regression of the lesions in approximately a quarter of patients when used as an adjunct to standard treatment (surgery, radiotherapy, systemic chemotherapy or hormone therapy) or when standard treatments are contraindicated. Complete remission was achieved in only 6% of cases in non comparative trials, and the median duration before progression resumed was 6 months. Miltefosine can have many local adverse effects.